EcoDrugPlus

Epoxide Hydrolase 2

Ensembl ID : ENSUPAG00010003940
Gene Symbol: EPHX2
3 Cross references
203 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSUPAG00010007639
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSUPAG00010015264
Gene Symbol: ERBB3
1 Cross references
282 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSUPAG00010016635
Gene Symbol: ERBB4
1 Cross references
236 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSUPAG00010013233
Gene Symbol: ESR1
1 Cross references
210 Possible Orthologues:

Estrogen Receptor 2

Ensembl ID : ENSUPAG00010011208
Gene Symbol: ESR2
3 Cross references
273 Possible Orthologues:

Estrogen Related Receptor Gamma

Ensembl ID : ENSUPAG00010009597
Gene Symbol: ESRRG
1 Cross references
277 Possible Orthologues:

Exportin 1

Ensembl ID : ENSUPAG00010011307
Gene Symbol: XPO1
3 Cross references
304 Possible Orthologues:

Farnesyl Diphosphate Synthase

Ensembl ID : ENSUPAG00010002775
Gene Symbol: FDPS
3 Cross references
265 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSUPAG00010023923
Gene Symbol: FDFT1
1 Cross references
215 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSUPAG00010017774
Gene Symbol: FNTA
1 Cross references
219 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSUPAG00010011581
Gene Symbol: FNTB
3 Cross references
210 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).